Copyright Reports & Markets. All rights reserved.

Global Non-small Cell Lung Cancer Drugs Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Non-small Cell Lung Cancer Drugs Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Biologics
      • 1.4.3 Small Molecule Targeted Therapy
      • 1.4.4 Chemotherapy
      • 1.4.5 Other
    • 1.5 Market by Application
      • 1.5.1 Global Non-small Cell Lung Cancer Drugs Market Share by Application (2019-2025)
      • 1.5.2 Lung Adenocarcinoma
      • 1.5.3 Squamous Cell Lung Carcinoma
      • 1.5.4 Large-cell Lung Carcinoma
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Non-small Cell Lung Cancer Drugs Market Size
    • 2.2 Non-small Cell Lung Cancer Drugs Growth Trends by Regions
      • 2.2.1 Non-small Cell Lung Cancer Drugs Market Size by Regions (2019-2025)
      • 2.2.2 Non-small Cell Lung Cancer Drugs Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Non-small Cell Lung Cancer Drugs Market Size by by Players
      • 3.1.1 Global Non-small Cell Lung Cancer Drugs Revenue by by Players (2014-2019)
      • 3.1.2 Global Non-small Cell Lung Cancer Drugs Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Non-small Cell Lung Cancer Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Non-small Cell Lung Cancer Drugs Key Players Head office and Area Served
    • 3.3 Key Players Non-small Cell Lung Cancer Drugs Product/Solution/Service
    • 3.4 Date of Enter into Non-small Cell Lung Cancer Drugs Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Non-small Cell Lung Cancer Drugs Market Size by Type (2014-2019)
    • 4.2 Global Non-small Cell Lung Cancer Drugs Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Non-small Cell Lung Cancer Drugs Market Size (2014-2019)
    • 5.2 Non-small Cell Lung Cancer Drugs Key Players in North America
    • 5.3 North America Non-small Cell Lung Cancer Drugs Market Size by Type
    • 5.4 North America Non-small Cell Lung Cancer Drugs Market Size by Application

    6 Europe

    • 6.1 Europe Non-small Cell Lung Cancer Drugs Market Size (2014-2019)
    • 6.2 Non-small Cell Lung Cancer Drugs Key Players in Europe
    • 6.3 Europe Non-small Cell Lung Cancer Drugs Market Size by Type
    • 6.4 Europe Non-small Cell Lung Cancer Drugs Market Size by Application

    7 China

    • 7.1 China Non-small Cell Lung Cancer Drugs Market Size (2014-2019)
    • 7.2 Non-small Cell Lung Cancer Drugs Key Players in China
    • 7.3 China Non-small Cell Lung Cancer Drugs Market Size by Type
    • 7.4 China Non-small Cell Lung Cancer Drugs Market Size by Application

    8 Japan

    • 8.1 Japan Non-small Cell Lung Cancer Drugs Market Size (2014-2019)
    • 8.2 Non-small Cell Lung Cancer Drugs Key Players in Japan
    • 8.3 Japan Non-small Cell Lung Cancer Drugs Market Size by Type
    • 8.4 Japan Non-small Cell Lung Cancer Drugs Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size (2014-2019)
    • 9.2 Non-small Cell Lung Cancer Drugs Key Players in Southeast Asia
    • 9.3 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Type
    • 9.4 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Application

    10 India

    • 10.1 India Non-small Cell Lung Cancer Drugs Market Size (2014-2019)
    • 10.2 Non-small Cell Lung Cancer Drugs Key Players in India
    • 10.3 India Non-small Cell Lung Cancer Drugs Market Size by Type
    • 10.4 India Non-small Cell Lung Cancer Drugs Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Non-small Cell Lung Cancer Drugs Market Size (2014-2019)
    • 11.2 Non-small Cell Lung Cancer Drugs Key Players in Central & South America
    • 11.3 Central & South America Non-small Cell Lung Cancer Drugs Market Size by Type
    • 11.4 Central & South America Non-small Cell Lung Cancer Drugs Market Size by Application

    12 International Players Profiles

    • 12.1 AstraZeneca
      • 12.1.1 AstraZeneca Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Non-small Cell Lung Cancer Drugs Introduction
      • 12.1.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Drugs Business (2014-2019))
      • 12.1.5 AstraZeneca Recent Development
    • 12.2 Bristol-Myers Squibb Company
      • 12.2.1 Bristol-Myers Squibb Company Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Non-small Cell Lung Cancer Drugs Introduction
      • 12.2.4 Bristol-Myers Squibb Company Revenue in Non-small Cell Lung Cancer Drugs Business (2014-2019)
      • 12.2.5 Bristol-Myers Squibb Company Recent Development
    • 12.3 Eli Lilly and Company
      • 12.3.1 Eli Lilly and Company Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Non-small Cell Lung Cancer Drugs Introduction
      • 12.3.4 Eli Lilly and Company Revenue in Non-small Cell Lung Cancer Drugs Business (2014-2019)
      • 12.3.5 Eli Lilly and Company Recent Development
    • 12.4 F. Hoffmann-La Roche Ltd
      • 12.4.1 F. Hoffmann-La Roche Ltd Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Non-small Cell Lung Cancer Drugs Introduction
      • 12.4.4 F. Hoffmann-La Roche Ltd Revenue in Non-small Cell Lung Cancer Drugs Business (2014-2019)
      • 12.4.5 F. Hoffmann-La Roche Ltd Recent Development
    • 12.5 Merck & Co., Inc.
      • 12.5.1 Merck & Co., Inc. Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Non-small Cell Lung Cancer Drugs Introduction
      • 12.5.4 Merck & Co., Inc. Revenue in Non-small Cell Lung Cancer Drugs Business (2014-2019)
      • 12.5.5 Merck & Co., Inc. Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
      The strong drug pipeline and drug approvals are one of the critical factors that will trigger the non-small cell lung cancer drugs market growth during the forecast period. With the increase in the prevalence of lung cancer, the need for a strong pipeline of disease-modifying drugs is also increasing.
      In 2018, the global Non-small Cell Lung Cancer Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Non-small Cell Lung Cancer Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non-small Cell Lung Cancer Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      AstraZeneca
      Bristol-Myers Squibb Company
      Eli Lilly and Company
      F. Hoffmann-La Roche Ltd
      Merck & Co., Inc.
      ...

      Market segment by Type, the product can be split into
      Biologics
      Small Molecule Targeted Therapy
      Chemotherapy
      Other

      Market segment by Application, split into
      Lung Adenocarcinoma
      Squamous Cell Lung Carcinoma
      Large-cell Lung Carcinoma

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Non-small Cell Lung Cancer Drugs status, future forecast, growth opportunity, key market and key players.
      To present the Non-small Cell Lung Cancer Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Non-small Cell Lung Cancer Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now